Recently approved by the FDA and European Medicines Agency, CAR-T cell therapy is a new treatment option for B-cell malignancies. Currently, CAR-T cells are manufactured in centralized facilities and face bottlenecks like complex scaling up, high costs and logistic operations. These difficulties are mainly related to the use of viral vectors and the requirement to expand CAR-T cells to reach the therapeutic dose. In this paper, by using Sleeping Beauty-mediated genetic modification delivered by electroporation, we show that CAR-T cells can be generated and used without the need for ex vivo activation and expansion, consistent with a point-of-care (POC) approach. Our results show that minimally manipulated CAR-T cells are effective in vivo against RS4;11 leukemia cells engrafted in NSG mice even when inoculated after only 4 hours of gene transfer. In an effort to better characterize the infused CAR-T cells, we show that 19BBz T lymphocytes infused after 24h of electroporation (where CAR expression is already detectable) can improve the overall survival and reduce tumor burden in organs of mice engrafted with RS4;11 or Nalm-6 B cell leukemia. A side-by-side comparison of POC approach with a conventional 8-day expansion protocol using Transact beads demonstrated that both approaches have equivalent antitumor activity in vivo. Our data suggests that POC approach is a viable alternative for the generation and use of CAR-T cells, overcoming the limitations of current manufacturing protocols. Its use has the potential to expand CAR immunotherapy to a higher number of patients, especially in the context of lowincome countries.
Introduction
In the last decade, CAR-T cell immunotherapy has shown considerable results in the treatment of different types of cancer, especially of patients with B cell malignancies, with ~80% of response rate in patients with B cell acute lymphoblastic leukemia (1, 2) and 52-82% response rate in patients with B cell lymphoma (3, 4) . This therapy consists of redirecting T lymphocytes to antigens expressed by tumor cells by expressing a chimeric receptor harboring an extracellular antigen recognition domain derived from an antibody, a transmembrane region and an intracellular domain for signaling and activation of the T lymphocyte (5) . Based on these results, anti-CD19 CAR-T cells were recently approved by the FDA and European Commission for use in USA and Europe, consisting in a new treatment option for patients with B cell malignancies. Similar therapies targeting antigens like CD22 (6, 7) , BCMA (8) (9) (10) and EGFRvIII (11) are currently being evaluated in clinical trials, which will further extend the clinical application of CAR-T cell therapy to other types of cancer and potentially improve the response rates in the diseases already approached by CAR-T cell therapies.
Currently, the prevailing CAR-T cell manufacturing process involves the use of retro or lentiviral vectors for delivering the transgene to purified T cells followed by an in vitro expansion protocol aimed at generating enough T lymphocytes to reach the target dose, ranging in general from 2-5x10 6 /kg (12) . This process, despite providing satisfactory performance in generating the currently approved therapies, will hardly meet the expected increase in demand for CAR-T cell therapies in the near future, both in terms of cost and time of production. Retroviral and lentiviral vectors are costly and cumbersome to produce in large batches, and their use requires that specific quality control assays regarding the presence of replication-competent retrovirus (RCR) are performed in the final product (13) . Moreover, use of retroviral vectors requires preactivation of T cells, which generally adds at least 2 days to the manufacturing process.
In combination with the current methods of T cell expansion, like Wave bioreactors, or G-REX flask, total production time ranges from 12 to 16 days (14) .
We and others have shown that the integrative, non-viral Sleeping Beauty (SB) transposon system is a suitable alternative to viral vectors in the process of CAR-T cell production (15) (16) (17) (18) . CAR-T cells generated by electroporation of mononuclear cells with SB plasmids (one encoding the CAR transgene and the other encoding the SB100x transposase) have antitumor activity in vitro and in vivo, while presenting long-term CAR expression. As a plasmid-based system, this method is less cumbersome and potentially has a reduced overall cost when compared to viral vectors. Moreover, different studies have shown that the transgene integration profile of SB vectors are close to random (19) (20) (21) , which confers an advantage over retroviral and lentiviral vectors that have an integration profile biased towards transcriptionally-active sites (22) (23) (24) .
Recently, Ghassemi et al reported that decreasing the time of in vitro T cell expansion increased its antitumor activity in vivo, and lower doses of CAR T cell were able to control leukemia growth (25) . This report goes in line with the literature, showing that considerable T cell differentiation occur after in vitro expansion, with less differentiated, central memory-like T cells being associated with improved antitumor activity in preclinical models (26) (27) (28) and patients (29) . In this proof-of-principle paper, we take this concept one step further and show that, by using SB transposon system and electroporation-based gene delivery, CAR-T cells can be generated and directly used for therapy, without the need of ex vivo activation and expansion protocols. We show that this point-of-care (POC) approach is efficient against two different B cell leukemia models (RS4;11 and Nalm-6), constituting a potential new method for the generation and application of CAR-T cell therapy.
Material and Methods

Plasmids: The 19BBz CAR sequence was supplied by Dr. Dario Campana (St Jude
Children's Research Hospital, Memphis, TN). The sequence was codon optimized and synthesized by Genscript (Piscataway, NJ) and a myc-tag was added between CD8ɑ signal peptide and scFv to allow flow cytometry-based detection as described elsewhere (15) . The transgene was cloned using AgeI/NotI sites in the transposon vector pT3 provided by Dr. Richard Morgan (NIH). The SB100x transposase which is encoded by plasmid pCMV-SB100x was provided by Dr Sang Won Han (Federal University of São Paulo [UNIFESP], Brazil).
Cell lines and primary cells:
Nalm-6 and RS4;11 were modified by lentivirus to express a fluorescent GFP protein as previously described (15) and were selected by fluorescence-activated cell sorting (FACS). These cells were cultivated RPMI (Gibco,CA) complete medium supplemented with 10% fetal calf serum, 2 mM L-Glu and 100 U/mL penicillin and 100 μg/mL streptomycin (Sigma-Aldrich, MO) at 37°C, 5% CO2. Peripheral Ethics Committee and performed in accordance with the Declaration of Helsinki.
PBMCs electroporation and expansion: For PBMCs genetic modification, we used
Lonza® Nucleofector® II electroporation system as described in Chicaybam, 2013 (30) .
Briefly, we transferred 10 7 or 3x10 7 cells with 100ul of 1SM buffer, 20ug of pT3-19BBz and 1ug SB100x plasmids into a 0.2 cm cuvette (Mirus Biotech®, Madison, WI) and cells were electroporated with the U-14 program. The mock condition was electroporated with SB100x plasmid only. Directly after electroporation, 1mL of RPMI medium supplemented with 2 mM L-glutamine, 20% fetal calf serum and IL-2 (50 U/mL; Proleukin, Zodiac) without antibiotic was added to the cuvette and cells were transferred to a 6-well plate.
After 4 hours or 24 hours resting in RPMI with 20% fetal calf serum, cells were centrifuged, resuspended in PBS and used for POC condition. For the expansion experiments, cells were activated with T Cell TransAct CD3/CD28 (Miltenyi Biotec, Germany) at 1:200 concentration 24h after electroporation and the next day the supernatant was removed to withdraw beads. For the experiment referring to Figure 4 , whole blood was incubated with RosetteSep™ Human T Cell Enrichment Cocktail (StemCell) for 15 min at the concentration of 30 μl to 1 ml of blood for purification of CD3+ cells. The cells were further processed as described above. For the in vitro experiment for Supplementary Fig. 1 , T cells were cultured for 3 days with 200U IL-2 and cytotoxicity assays were performed as described below. 
Results
Evaluation of the potential antileukemic effect of the point-of-care approach.
Point of care approaches have the potential to simplify and broaden CAR-T based therapies. In order to demonstrate the feasibility of this approach, we validated this strategy in vivo in preclinical models. First, we validated POC based protocol ability to restrain leukemia growth by injecting 5x10 6 RS4;11 GFP cells in NSG mice on d+0, as demonstrated at the timeline (Fig. 1A) . Three days later, PBMC from a healthy donor were isolated and electroporated with the pT3-19BBz plasmid (anti-CD19 CAR with 41BB and CD3ζ domains) and SB100x (the transposase that mediates transgene integration). Cells were rested for 4 hours and then 10 7 total cells were inoculated to treat each mouse. After 24 hours of electroporation, we evaluated CAR expression by myctag detection in vitro. A total of 6,2x10 5 CAR-T cells were injected into each animal ( Fig.   1B ).
During the experiment, we analyzed tumor burden by measuring RS4;11 GFP expression in the blood of animals over time (Fig. 1C ). The group that received 19BBz CAR-T cells showed a decreased tumor burden in blood when compared to PBS treated mice (p=0.0004). Mock and 19BBz groups showed a lower statistical difference in blood leukemia burden (p=0.0196), suggesting an antitumor activity by untransfected cells.
This lower tumor burden also impacted the survival curve ( Fig. 1D ), demonstrating an improvement in mock group when compared with PBS treated mice (p=0.0278).
Interestingly, 19BBz cells were able to greatly improve the overall survival of mice when compared to mock cells. At day 60, all 19BBz animals remained alive and were euthanized, the tumor burden of organs was then checked by flow cytometry and compared between groups (Fig. 1E) . PBS group presented a high tumor burden in all organs analyzed and no significant difference was observed between mock and 19BBz, except for bone marrow, where 19BBz treated mice showed lower tumor burden.
The survival curve and bone marrow tumor burden indicate the effectiveness potential of the POC approach. Cells used 4 hours after electroporation do not yet express the CAR molecule, rendering impossible to evaluate the number of CAR-T cells infused in advance (such evaluation can only be performed at least 24h post gene transfer).
We usually evaluated CAR expression 24 hours after electroporation and, when we evaluated 5 donors for 3 days in vitro by keeping T cells in minimal culture conditions (without activation), CAR expression percentages remained overall stable ( Supplementary Fig. 1A-B ), so we can assume flow cytometry evaluation of CAR expression at 24h is a bona fide readout for CAR-T cell number evaluation. The in vitro antitumor capacity of CAR-T cells was low or absent and was similar to mock cells in the cytotoxicity assay against RS4;11 and Nalm-6 in these three days after electroporation ( Supplementary Fig. 1C ). In addition, CAR expression was restricted to CD3+ cells, with low or absent CAR expression in CD19+ or CD56+ cells ( Supplementary Fig. 2 ) Since the 24h rest enables CAR-T expression evaluation before injection, we decided to check for CAR-T cell antitumor potential after this short period of incubation. RS4;11 leukemia cells were engrafted in NSG animals and 3 days later CAR-T from 4h or 24h post electroporation from the same donor were injected in equivalent numbers for both groups ( Fig. 2A) . PBMC composition using CD14, CD19 and CD56 markers was similar in both groups (Fig. 2B) , with most of the cells being T lymphocytes (CD14-CD19-CD56-). T cell memory populations were determined among CD4+ and CD8+ cells ( We adjusted the number of total cells injected to 10 6 for all groups. After 24 hours of electroporation, the CAR expression could be detected in about 4% of the cells, meaning that 4x10 4 CAR-T positive cells were injected (Fig. 2D ). All the 19BBz conditions outperformed the corresponding mock conditions, both for 4h and 24h resting cells ( Fig.   2E ). When comparing 4h vs 24h between mock or 19BBz conditions, 24h resting seems to present a slight tendency to provide better survival, although statistical significance was never reached.
The RS4;11 model represents a valuable leukemia model that can reach very high tumor load in the periphery by day 21 and still allow the animals to survive for a few weeks, killing the mice by day 45 (Fig. 1D) . In order to validate these results in a more aggressive mouse model, we tested the same approach in NSG mice engrafted with Nalm-6 leukemia, which leads to animal death by day 21. Effectiveness of the point-of-care approach in animals engrafted with Nalm-6
The Nalm-6 cell line is widely used and is a well-established model in several works with CAR-T cell therapies (32) (33) (34) . We injected 10 5 Nalm-6 per animal and treated the groups with CAR-T cells two days later (Fig. 3A) . Using the 24h POC CAR-T generation approach, 18,5% of the cells showed CAR expression 24h after electroporation (Fig. 3B) and a total of 7x10 5 CAR-T cells were injected into each animal. The 19BBz treated group largely outperformed both PBS and mock treated groups in survival analysis (Fig. 3C ).
PBS and mock groups showed no difference in survival curve, indicating that mock electroporated cells have no antitumor activity in this model. After euthanasia, the 19BBz group showed lower tumor burden in all the evaluated organs when compared with the other groups, except in bone marrow. This inversion of tumor burden may be due to the longer survival time of the 19BBz group that allowed the accumulation of tumor cells in this organ. (Fig. 3D ). 
Antitumor activity of Point-of-care and anti CD3/CD28 beads expanded cells
If a POC approach is to be used clinically, it should perform at least as well as the current bead-based expansion protocols. Hence, we conducted experiments to compare both approaches side-by-side. We divided the animals into two groups, POC and Expansion and used the same donor as source of T cells, adjusting the dose of CAR-T cells infused to be equal for both conditions.
On this occasion we purified T cells from PBMCs to ensure no antitumor effect by natural killer (NK) cells and ensure cell composition homogeneity in both groups by injecting only CD3+ cells. As previously described by our group, NK cells may have accounted for improved survival of the mock group compared to PBS treated animals when the infused product contains this lymphocyte population (15) . T cells were electroporated and infused into the animals after 24 hours in the POC group. A fraction of the cells from the same electroporation were stimulated with CD3/CD28 Transact beads and expanded for 8 days. Figure 4A shows the expansion of these cells in culture, with 19BBz cells displaying higher expansion capabilities when compared to the mock electroporated cells. As expected, the memory cell profiles changed over the in vitro culture period. Only low levels of CD4+ and CD8+ Naive T cells could be detected after 8 days of culture and the lymphocytes consisted basically of CM cells at the end of the culture for both CD4 and CD8 subsets (Fig. 4B ).
CAR expression was evaluated by cytometry to match the same number of CAR-T cells in POC and Expansion treated groups (Fig. 4C) . We tested two different CAR-T cell numbers, injecting 1,5x10 5 or 1,5x10 4 CAR+ cells in two separate groups. Mock condition animals received 1,4x10 6 total cells. We analyzed the percentage of GFP cells in spleen, bone marrow, blood and liver after euthanasia and the group that received the largest number of CAR-T cells showed the lowest tumor burden in almost all cases in both the POC and Expansion groups (Fig. 4D ).
Survival of animals from the POC group proved to be similar to that of the Expansion group (Fig. 4E) . In both cases, all animals receiving any dose of CAR-T cells had improved survival. No consistent dose-response effect was observed between 19BBz groups: POC p(1,5x10 4 vs 1,5x10 5 19BBz) = 0,0692 and Expansion p(1,5x10 4 vs 1,5x10 5 19BBz) = 0,6034.
This experiment was repeated using similar conditions. In this case, cells were expanded for 12 days and no change in CAR-T cell percentage was observed ( Supplementary Fig.   3A ). Central memory cells were also the major population after expansion ( Supplementary Fig. 3B ). Survival of animals from the POC group proved to be similar to that of the Expansion group using the same CAR-T cell dose. In this model, a higher dose of CAR-T cell confers a longer overall survival from both POC and Expansion groups ( Supplementary Fig. 3C ). Our data indicates that the antitumor capacity of the POC approach is comparable to the potency of the bead-based expansion protocol, indicating that POC based CAR therapy can be proposed as a clinical strategy. 
Discussion
CAR-T cells are now being successfully used for the treatment of B cell leukemias
and lymphomas, constituting a new treatment option for these malignancies. Further developments in target antigen selection, CAR design and combination therapy are likely to extend CAR-T cell therapy to solid tumors (35, 36) . Thus, large scale production capabilities need to be developed in order to meet this expected increase in demand in the next years.
Current methods used for autologous CAR-T cell manufacturing rely on viral vector transduction and ex vivo expansion protocols to generate the therapeutic product, procedures that are difficult to scale up and that require skilled technicians. In an attempt to optimize production, companies opted for centralized production facilities that supply CAR-T cell therapies to qualified treatment centers, but this also imposes a considerable logistic challenge that contributes to the complexity of this treatment modality (37) . Indeed, 7 of 88 patients enrolled in the ELIANA trial could not be treated with tisagenlecleucel due to manufacturing failures (38) . Moreover, some patients with advanced disease may succumb to the disease prior to receiving the therapy. These aspects, combined with long (12-20 days) production time and high costs, constitute important bottlenecks for the widespread use of this technology. The use of automated CAR-T cell production equipments (for example, Miltenyi Prodigy) will likely improve the process, but the high upfront costs of acquisition and lack of customization might hamper their use in the short term (39, 40) .
Meanwhile, preclinical and clinical data is showing that T cells with a less differentiated phenotype, such as naïve or central memory T cells, have improved antitumor responses in vivo (41) (42) (43) . In fact, a recent report described that the presence of a memory-like CD27+CD45RO-CD8+ T cell subpopulation was associated with improved responses in patients with chronic lymphocytic leukemia treated with anti-CD19 CAR-T cells (27) . However, current T cell manufacturing protocols are not optimized to generate or expand these cell types and generally induce T cell differentiation, mainly related to exposure to cytokines like IL-2 (44, 45) . Importantly, it was recently shown that producing CAR-T cells using a shorter (3-5 days) expansion protocol can induce less T cell differentiation, reducing the expression of inhibitory receptors and improving effector function (41, 42) . Importantly, it was recently shown that producing CAR-T cells using a shorter (3-5 days) expansion protocol can induce less T cell differentiation, reducing the expression of inhibitory receptors and improving effector function (25) .
In this context, the use of SB system associated to nucleofection provides a compelling approach for the fast generation of minimally manipulated CAR-T cells. Being a plasmid-based, integrative genetic modification tool, this system can be delivered by electroporation and generate large numbers of CAR-T cells in a short time, consistent with a POC approach. As we showed in this report, T cells electroporated with 19BBz CAR and injected after only 4h induce increased survival of mice engrafted with RS4;11 B cell leukemia when compared to mock T cells ( Fig. 1) . A similar result was obtained when 19BBz were rested in culture for 24h after electroporation, demonstrating that 4x10 4 CAR+ T cells are already sufficient to induce an increased survival in mice engrafted with RS4;11 B cell leukemia (Fig. 2) . This is important since, for regulatory reasons, the 24h cultivation would allow rapid tests for sterility to be performed and minimal phenotypic characterization of the cells, such as CAR detection on T lymphocytes and dose adjustments to reduce potential toxicities. Supporting this idea, our data show that CAR expression at d+1 post nucleofection represents roughly the peak of CAR expression ( Supplementary Fig. 1 ) and can be used as a proxy for CAR-T cell infusion doses. Our results also indicate that CAR-T cells at d+1 post CAR gene transfer do not display significant leukemia lysis capabilities in vitro, reinforcing the notion that these minimally manipulated CAR-T cells will expand and differentiate in vivo, acquiring their final phenotype and cytotoxic functions.
Our experiments also demonstrated that 19BBz CAR-T used in POC approach showed antitumor responses in a more aggressive B cell leukemia model using the Nalm-6 cell line. As shown in figure 3 , 19BBz CAR-T cells induced improved overall survival and decreased tumor burden in blood, spleen and liver when compared to mock T cells. It is important to note that 7x10 5 CAR-T cell were required to induce this response, as numbers lower than this were not effective in vivo (data not shown). Finally, side by side comparison of CAR-T cells generated after 8 days of ex vivo expansion with CAR-T cells used with POC approach showed equivalent efficiency in vivo in terms of percentage of tumor cells in organs ( Fig. 4D ) and overall survival (Fig. 4E ), despite showing different distribution of T cell memory subpopulations in the cell preparations ( Fig. 4B and Supplementary Fig. 3 ).
The results presented in this paper demonstrate the feasibility of the POC approach. The use of large-scale, closed electroporation systems, like Lonza Nucleofector 4D LV unit or Maxcyte`s electroporator, can process large quantities (up to 20x10 9 cells per run) of PBMCs (46) and generate minimally-manipulated CAR-T cells in a short time, being compatible with GMP procedures. It was recently reported that 1.18 -298x10 9 PBMCs (median: 8.83 x10 9 cells) can be recovered after apheresis of pediatric and young adult patients with B-ALL or neuroblastoma enrolled in CAR clinical trials (47) .
A second paper reported recoveries ranging 0.12-100x10 9 of PBMCs (median: 10.5x10 9 ) in adult patients (48) . Assuming 50% viability and 10% transfection efficiency, by processing around 3x10 9 PBMCs it would be possible to generate 15x10 7 CAR+ T cells, equivalent to 2.1x10 6 CAR+ T cells/kg for a 70kg patient. Therefore, production of CAR-T cells for POC approach using currently available devices is potentially feasible and compatible with T cell doses used in the clinical practice. Nonetheless, the minimal manipulation of our POC approach has the potential to generate cells in better shape to provide leukemia protection in vivo, so the minimal doses required for in vivo function in patients are still to be determined.
The proposed approach in this report can be further potentiated with additional manipulations of T cells such as the addition of cytokines or immune checkpoint blockade secretion by T cells, as already described (49) . In any case, the absence of an ex vivo expansion phase simplifies the CAR-T manufacturing process and has the potential to drastically decrease the overall cost, facilitating the adoption of this new therapy, especially in developing countries.
